Abstract：Objective To analyze the safety of Ticagrelor as an adjuvant therapy for patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods From March 2018 to May 2020,60 ACS patients in Taishan People′s Hospital were selected as research subjects.According to the random number table method,they were divided into the control group and the study group,with 30 cases in each group.PCI was implemented according to China PCI Treatment Guideline 2012(concise).Patients after admission in the two groups were given load dose/conventional dose of Aspirin after PCI.In the control group,the load dose/conventional dose of Clopidogrel in oral administration after PCI was used;in the study group,oral administration of Ticagrelor at a load dose/conventional dose was added after PCI.The adverse cerebrovascular events,bleeding events,and adverse reactions were compared between the two groups within six months after surgery.Results There was no significant difference in the incidence of adverse cerebrovascular events after surgery in the two groups(P＞0.05).The incidence of postoperative bleeding events after surgery was lower than that of the control group,the difference was statistically significant(P＜0.05).The incidence of postoperative adverse reactions in the study group was lower than that of the control group,the difference was statistically significant(P＜0.05).Conclusion Ticagrelor has more advantages than Clopidogrel in reducing the incidence of adverse events and adverse reactions in patients with ACS,which is worthy of clinical promotion and application.
赵钻华;谭嘉劲 ;谭顺沛. 替格瑞洛辅助用于急性冠脉综合征患者经皮冠状动脉介入治疗后的安全性分析[J]. 中国当代医药, 2021, 28(17): 152-154转158.
ZHAO Zuan-hua;TAN Jia-jin; TAN Shun-pei. Safety analysis of Ticagrelor as an adjuvant medication for patients with acute coronary syndrome after percutaneous coronary intervention. 中国当代医药, 2021, 28(17): 152-154转158.
京公网安备 11010502046607号